甲氨蝶呤治疗慢性基孔肯雅关节炎:一项系统综述
该系统综述检索了截至2017年8月的多个数据库,评估甲氨蝶呤(MTX)单药或联合治疗慢性基孔肯雅关节炎的疗效与安全性。共纳入6项研究(4项回顾性研究、1项非对照前瞻性研究、1项非盲随机临床试验);该随机试验中MTX联合羟氯喹和柳氮磺吡啶的三联疗法优于羟氯喹单药治疗。作者认为MTX疗效足以支持进一步研究,但现有试验设计不严谨、治疗策略和结局指标各异。
要点
- 共纳入6项研究评估MTX治疗慢性基孔肯雅关节炎,其中4项为回顾性研究。
- 唯一随机试验中MTX三联疗法在DAS28-ESR和HAQ上均优于羟氯喹单药。
- 现有试验设计不严谨、治疗策略和结局指标不同,作者强调需随机前瞻性安慰剂对照研究。
核心结论
- 现有研究数量有限,但综合来看这些研究显示MTX疗效足以支持进一步研究其治疗慢性基孔肯雅关节炎。
- 作者指出这些试验缺乏严谨的研究设计,并使用了不同的治疗策略和结局指标。
- 本系统综述强调需要对MTX单药治疗慢性基孔肯雅关节炎开展随机、前瞻性、安慰剂对照研究。
研究设计与样本
- 系统文献检索评估MTX单药或联合治疗慢性基孔肯雅关节炎患者的所有已发表试验。
- 检索PubMed、SciELO、Scopus和Cochrane Library数据库,检索时间从建库至2017年8月。
- 同时检索Google Scholar、国际临床试验注册平台检索门户和clinicaltrials.gov。
- 131项可能相关研究中6项符合评价标准:4项回顾性研究、1项非对照前瞻性研究、1项非盲随机临床试验(联合MTX治疗)。
主要发现
- 在随机临床试验中,MTX、羟氯喹和柳氮磺吡啶三联疗法在DAS28-ESR上优于羟氯喹单药(3.39±0.87 vs 4.74±0.65;P<0.0001)。
- 在随机临床试验中,三联疗法在健康评估问卷(HAQ)评分上优于羟氯喹单药(1.14±0.31 vs 1.88±0.47;P<0.0001)。
关键数值与推荐
- DAS28-ESR:MTX三联疗法组3.39±0.87 vs 羟氯喹单药组4.74±0.65(P<0.0001)。
- HAQ评分:MTX三联疗法组1.14±0.31 vs 羟氯喹单药组1.88±0.47(P<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 现有研究数量有限。
- 这些试验缺乏严谨的研究设计。
- 这些试验使用了不同的治疗策略和结局指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chikungunya virus infection is a rapidly emerging global viral infection that can cause chronic, debilitating arthritis that in some ways mimics rheumatoid arthritis. The aim of this study was to evaluate the available evidence regarding the efficacy and safety of methotrexate (MTX), a therapy that is widely used in rheumatoid arthritis, for the treatment of chronic chikungunya arthritis. METHODS: A systematic literature search was performed to identify all published trials that evaluated MTX as monotherapy or combination therapy in patients with chronic chikungunya arthritis. PubMed, SciELO, Scopus, and Cochrane Library databases were searched from study inception to August 2017. We also searched Google Scholar, the International Clinical Trials Registry Platform Search Portal, and clinicaltrials.gov. RESULTS: Among 131 possibly relevant studies, 6 met our criteria for evaluation: 4 were retrospective studies, 1 was a non-controlled prospective study, and 1 was an unblinded randomized clinical trial of combination MTX therapy. In the randomized clinical trial, triple therapy with MTX, hydroxychloroquine, and sulfasalazine was superior to hydroxychloroquine monotherapy, as assessed by the mean ± SD Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (3.39 ± 0.87 versus 4.74 ± 0.65; P < 0.0001) and the Health Assessment Questionnaire score (1.14 ± 0.31 versus 1.88 ± 0.47; P < 0.0001). CONCLUSION: The number of available studies is limited, but taken together, these studies demonstrate that MTX is sufficiently efficacious to justify further study of MTX for the treatment of chronic chikungunya arthritis. The trials lacked rigorous study designs and used different treatment strategies and outcome measures. This systematic review underscores the need for randomized, prospective, placebo-controlled studies of MTX monotherapy for the treatment of chronic chikungunya arthritis.
引用
- Amaral JK, Sutaria R, Schoen RT, et al. Treatment of Chronic Chikungunya Arthritis With Methotrexate: A Systematic Review. Arthritis Care Res (Hoboken). 2018. PMID: 29361202. doi:10.1002/acr.23519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。